http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
The BRAHMS Experiment at the Relativistic Heavy Ion Collider
Y. K. Lee,I. G. Bearden,D. Beavis,C. Besliu,Y. Blyakhman,J. Brzychczyk,B. Budick,H. Bggild,C. Chasman,C. H. Christensen,P. Christiansen,J. Cibor,R. Debbe,E. Enger,J. J. Gaardhje,K. Grotowski,K. Hagel 한국물리학회 2003 THE JOURNAL OF THE KOREAN PHYSICAL SOCIETY Vol.43 No.I
The BRAHMS probes the hot and dense nuclear matter at the RHIC which has reached its design energy of psNN = 200 GeV for Au + Au collisions. The BRAHMS uses magnetic spectrometers for hadrons covering a large phase space 0 < y < 4 with good particle identification and momentum resolution. A comprehensive investigation of multiplicity distributions of emitted charged particles is carried out. Ratios of yields of antiparticles to particles are also measured as a function of rapidity. Rapidity dependent net-proton yield indicates that substantial transparency has been achieved in these collisions. Transverse momentum spectra of charged hadrons are measured up to 5 GeV/c which indicates a significant medium eect when compared to nucleon + nucleon reference spectra.
Genome Wide Proteomics of ERBB2 and EGFR and Other Oncogenic Pathways in Inflammatory Breast Cancer
Zhang, Emma Yue,Cristofanilli, Massimo,Robertson, Fredika,Reuben, James M.,Mu, Zhaomei,Beavis, Ronald C.,Im, Hogune,Snyder, Michael,Hofree, Matan,Ideker, Trey,Omenn, Gilbert S.,Fanayan, Susan,Jeong, S American Chemical Society 2013 Journal of proteome research Vol.12 No.6
<P>In this study we selected three breast cancer cell lines (SKBR3, SUM149 and SUM190) with different oncogene expression levels involved in ERBB2 and EGFR signaling pathways as a model system for the evaluation of selective integration of subsets of transcriptomic and proteomic data. We assessed the oncogene status with reads per kilobase per million mapped reads (RPKM) values for ERBB2 (14.4, 400, and 300 for SUM149, SUM190, and SKBR3, respectively) and for EGFR (60.1, not detected, and 1.4 for the same 3 cell lines). We then used RNA-Seq data to identify those oncogenes with significant transcript levels in these cell lines (total 31) and interrogated the corresponding proteomics data sets for proteins with significant interaction values with these oncogenes. The number of observed interactors for each oncogene showed a significant range, e.g., 4.2% (JAK1) to 27.3% (MYC). The percentage is measured as a fraction of the total protein interactions in a given data set vs total interactors for that oncogene in STRING (Search Tool for the Retrieval of Interacting Genes/Proteins, version 9.0) and I2D (Interologous Interaction Database, version 1.95). This approach allowed us to focus on 4 main oncogenes, ERBB2, EGFR, MYC, and GRB2, for pathway analysis. We used bioinformatics sites GeneGo, PathwayCommons and NCI receptor signaling networks to identify pathways that contained the four main oncogenes and had good coverage in the transcriptomic and proteomic data sets as well as a significant number of oncogene interactors. The four pathways identified were ERBB signaling, EGFR1 signaling, integrin outside-in signaling, and validated targets of C-MYC transcriptional activation. The greater dynamic range of the RNA-Seq values allowed the use of transcript ratios to correlate observed protein values with the relative levels of the ERBB2 and EGFR transcripts in each of the four pathways. This provided us with potential proteomic signatures for the SUM149 and 190 cell lines, growth factor receptor-bound protein 7 (GRB7), Crk-like protein (CRKL) and Catenin delta-1 (CTNND1) for ERBB signaling; caveolin 1 (CAV1), plectin (PLEC) for EGFR signaling; filamin A (FLNA) and actinin alpha1 (ACTN1) (associated with high levels of EGFR transcript) for integrin signalings; branched chain amino-acid transaminase 1 (BCAT1), carbamoyl-phosphate synthetase (CAD), nucleolin (NCL) (high levels of EGFR transcript); transferrin receptor (TFRC), metadherin (MTDH) (high levels of ERBB2 transcript) for MYC signaling; S100-A2 protein (S100A2), caveolin 1 (CAV1), Serpin B5 (SERPINB5), stratifin (SFN), PYD and CARD domain containing (PYCARD), and EPH receptor A2 (EPHA2) for PI3K signaling, p53 subpathway. Future studies of inflammatory breast cancer (IBC), from which the cell lines were derived, will be used to explore the significance of these observations.</P><P><B>Graphic Abstract</B> <IMG SRC='http://pubs.acs.org/appl/literatum/publisher/achs/journals/content/jprobs/2013/jprobs.2013.12.issue-6/pr4001527/production/images/medium/pr-2013-001527_0010.gif'></P><P><A href='http://pubs.acs.org/doi/suppl/10.1021/pr4001527'>ACS Electronic Supporting Info</A></P>
Mohan Hingorani,Sanjay Dixit,Miriam Johnson,Victoria Plested,Kevin Alty,Peter Colley,Andrew W. Beavis,Rajarshi Roy,Anthony Maraveyas 대한암학회 2015 Cancer Research and Treatment Vol.47 No.4
Purpose We report the outcomes of patients treated with palliative radiotherapy (pRT) to the primarytumour in the context of well-controlled metastatic disease after initial chemotherapy. Materials and MethodsClinical records of 132 patients with metastatic esophago-gastric (OG) cancer treated withpalliative chemotherapy (pCT) between January 2009 and June 2013 were reviewed. Ninetysevenpatients had responding or stable disease after 3 months of chemotherapy, of whom53 patients received pRT to the primary tumour after initial chemotherapy in the presenceof well-controlled metastatic disease (group A, pCT-RT). The remaining 44 patients weretreated with pCT alone (group B, pCT). Treatment-related outcomes were assessed in abovegroups including time to local progression (TTLP), progression-free and overall survival. ResultsThe median overall survival for patients treated with pRT after initial chemotherapy (groupA) was 23.3 months (95% confidence interval [CI], 17.70 to 28.89 months) and significantlyhigher than the 14 months (95% CI, 10.91 to 17.08 months) in patients treated with pCTalone (group B) (p < 0.001). The use of pCT-RT was an independent predictor of OS in multivariateanalysis. Local recurrence was observed in 12/53 of patients (23%) in group Acompared to 16/44 (36%) in group B. The median TTLP was significantly higher in patientsafter pCT-RT at 17.3 months (5.23 months to 44.50 months) compared to 8.3 months(range, 4.10 to 25.23 months) in patients treated with pCT alone (p=0.006). ConclusionThe possibility of pRT influencing systemic disease in advanced OG cancer has not beenreported, and results from the present study present strong arguments for investigation ofthis therapeutic strategy in a randomized trial.
Longitudinal spin transfer toΛandΛ¯hyperons in polarized proton-proton collisions ats=200 GeV
Abelev, B. I.,Aggarwal, M. M.,Ahammed, Z.,Alakhverdyants, A. V.,Anderson, B. D.,Arkhipkin, D.,Averichev, G. S.,Balewski, J.,Barannikova, O.,Barnby, L. S.,Baumgart, S.,Beavis, D. R.,Bellwied, R.,Benedo American Physical Society 2009 PHYSICAL REVIEW D - Vol.80 No.11
Observation of an Antimatter Hypernucleus
Abelev, B. I.,Aggarwal, M. M.,Ahammed, Z.,Alakhverdyants, A. V.,Alekseev, I.,Anderson, B. D.,Arkhipkin, D.,Averichev, G. S.,Balewski, J.,Barnby, L. S.,Baumgart, S.,Beavis, D. R.,Bellwied, R.,Betancour American Association for the Advancement of Scienc 2010 Science Vol.328 No.5974
Scaling properties at freeze-out in relativistic heavy-ion collisions
Aggarwal, M. M.,Ahammed, Z.,Alakhverdyants, A. V.,Alekseev, I.,Alford, J.,Anderson, B. D.,Anson, C. D.,Arkhipkin, D.,Averichev, G. S.,Balewski, J.,Barnby, L. S.,Beavis, D. R.,Bellwied, R.,Betancourt, American Physical Society 2011 PHYSICAL REVIEW C - Vol.83 No.3
Charged-to-neutral correlation at forward rapidity in Au + Au collisions at<sub>sNN</sub>=200GeV
Adamczyk, L.,Adkins, J. K.,Agakishiev, G.,Aggarwal, M. M.,Ahammed, Z.,Alekseev, I.,Alford, J.,Anson, C. D.,Aparin, A.,Arkhipkin, D.,Aschenauer, E. C.,Averichev, G. S.,Banerjee, A.,Beavis, D. R.,Bellwi American Physical Society 2015 PHYSICAL REVIEW C - Vol.91 No.3
STAR Collaboration,Agakishiev, G.,Aggarwal, M.M.,Ahammed, Z.,Alakhverdyants, A.V.,Alekseev, I.,Alford, J.,Anderson, B.D.,Anson, C.D.,Arkhipkin, D.,Averichev, G.S.,Balewski, J.,Beavis, D.R.,Behera, N.K North-Holland Pub. Co 2011 Physics letters: B Vol.704 No.5
We present first measurements of the evolution of the differential transverse momentum correlation function, C, with collision centrality in Au+Au interactions at s<SUB>NN</SUB>=200 GeV. This observable exhibits a strong dependence on collision centrality that is qualitatively similar to that of number correlations previously reported. We use the observed longitudinal broadening of the near-side peak of C with increasing centrality to estimate the ratio of the shear viscosity to entropy density, η/s, of the matter formed in central Au+Au interactions. We obtain an upper limit estimate of η/s that suggests that the produced medium has a small viscosity per unit entropy.